AM Pharma to Participate in Upcoming Investor Conferences
AM Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg, the Company’s Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, will participate in the following investor conferences:
- Kempen’s 40th Annual Life Sciences Virtual Crossover Conference on Thursday, January 6, 2022. The Company will be conducting investor meetings, which can be requested through Kempen.
- H.C. Wainwright’s BioConnect Virtual Conference on Monday, January 10, 2022 at 7:00 a.m. Eastern Time.
The H.C. Wainwright presentation will be available on the Investors section of the Company’s website at www.am-pharma.com . A replay of the webcast will be archived and available for 90 days following the event.
AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals. Find out more about us online at: www.am-pharma.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-GIANT-PROTOCOL27.1.2022 16:25:07 CET | Press release
GIANT Protocol Publishes Litepaper for Decentralized Internet Connectivity Economy
LUNAPHORE27.1.2022 16:02:13 CET | Press release
Lunaphore appoints Alice Feng as Chief Financial Officer
CROMA-PHARMA27.1.2022 15:28:08 CET | Press release
Croma-Pharma Completed the Decentralized Procedure for Its Botulinum Toxin to Treat Glabellar (frown) Lines
TVP-SOLAR27.1.2022 15:20:05 CET | Press release
PepsiCo Implements TVP Solar Thermal Plant for Renewable Heat and Saves 140’000 M³ of Natural Gas at the Sete Lagoas Factory (MG)
NY-MOODY’S27.1.2022 15:17:04 CET | Press release
Moody’s Again Earns Top LGBTQ+ Corporate Equality Score From Human Rights Campaign
NY-GENESIS27.1.2022 15:02:10 CET | Press release
Genesis Q4 Report Highlights Key Trends from 2021 in Crypto Lending, Trading and Custody
TX-MAVENIR27.1.2022 15:02:10 CET | Press release
Mavenir’s Cloud-Native Open vRAN and Packet Core Achieves GSMA NESAS Security Certification
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom